{"id":542948,"date":"2021-05-12T19:10:01","date_gmt":"2021-05-12T19:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542948"},"modified":"2021-05-12T19:10:01","modified_gmt":"2021-05-12T19:10:01","slug":"cushings-syndrome-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cushings-syndrome-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_542948.html","title":{"rendered":"Cushing\u2019s Syndrome Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | Delveinsight"},"content":{"rendered":"
\"Cushing’s<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Cushing’s Syndrome – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cushing’s Syndrome, historical and forecasted epidemiology as well as the Cushing’s Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Cushing’s Syndrome (CS) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/p>\n

DelveInsight’s “Cushing’s Syndrome (CS) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report delivers an in-depth understanding of the  Cushing’s Syndrome (CS), historical and forecasted epidemiology as well as the  Cushing’s Syndrome (CS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    According to the Orphanet, the prevalence of endogenous Cushing’s Syndrome (CS) is 1\/26,000 and, in the EU, it has an annual prevalence of 1\/1,400,000-1\/400,000, with a peak prevalence at 25-40 years of age.<\/p>\n<\/li>\n

  2. \n

    As per the research, although it may occur in children, Cushing’s syndrome most commonly affects adults between the ages of 25 to 40.<\/p>\n<\/li>\n

  3. \n

    As per a study, the prevalence of Cushing’s disease maybe 5 to 25 per million per year. However, the reported prevalence was much lower (1.2 to 2.4 per million per year) in one population-based study. In a United States study, the prevalence was higher than previously reported in European studies as it was found to affect 6.2 to 7.6 per million person-years.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Cushing’s Syndrome (CS) market report covers a descriptive overview and comprehensive insight of the Cushing’s Syndrome (CS) epidemiology and Cushing’s Syndrome (CS) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. Cushing’s Syndrome (CS) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Cushing’s Syndrome (CS) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Cushing’s Syndrome (CS) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the  Cushing’s Syndrome (CS) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/cushings-syndrome-market<\/span><\/a><\/strong><\/p>\n

    Cushing’s Syndrome (CS): Overview<\/strong><\/p>\n

    Cushing’s syndrome (CS) is a rare problem caused when the adrenal gland(s) makes too much of a hormone called cortisol. CS is most often due to a tumor or mass found in the pituitary gland, but can also be caused by tumors in the adrenal glands themselves.<\/p>\n

    People with Cushing’s syndrome may see their face get round (“moon face”), they gain weight in unusual ways, bruise easily or feel weak, tired and sad. Women and men may also notice fertility and other problems. CS is most often found in adults between the ages of 20 and 50.<\/p>\n

    The key player involved in Cushing’s Syndrome (CS) market<\/a>:<\/strong><\/p>\n

      \n
    1. \n

      Recordati, <\/p>\n<\/li>\n

    2. \n

      Corcept Therapeutics, <\/p>\n<\/li>\n

    3. \n

      Millendo Therapeutics, <\/p>\n<\/li>\n

    4. \n

      Cortendo, <\/p>\n<\/li>\n

    5. \n

      SteroTherapeutics<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Cushing’s Syndrome (CS) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        Osilodrostat <\/p>\n<\/li>\n

      2. \n

        Relacorilant <\/p>\n<\/li>\n

      3. \n

        ATR-101 <\/p>\n<\/li>\n

      4. \n

        Levoketoconazole <\/p>\n<\/li>\n

      5. \n

        ST-002 <\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/cushings-syndrome-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Cushing’s Syndrome (CS) Patient Share (%) Overview at a Glance<\/p>\n

        5. Cushing’s Syndrome (CS) Market Overview at a Glance<\/p>\n

        6. Cushing’s Syndrome (CS) Disease Background and Overview<\/p>\n

        7. Cushing’s Syndrome (CS) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of  Cushing’s Syndrome (CS)<\/p>\n

        9. Cushing’s Syndrome (CS) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Cushing’s Syndrome (CS) Emerging Therapies<\/p>\n

        12. Cushing’s Syndrome (CS) Market Outlook<\/p>\n

        13. Country-Wise Cushing’s Syndrome (CS) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Cushing’s Syndrome (CS) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Cushing’s Syndrome (CS)- Pipeline Insights, 2021<\/strong><\/p>\n

        “Cushing’s Syndrome (CS) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the  Cushing’s Syndrome (CS) market. A detailed picture of the  Cushing’s Syndrome (CS) pipeline landscape is provided, which includes the disease overview and  Cushing’s Syndrome (CS) treatment guidelines.<\/p>\n

        Cushing’s Syndrome (CS) – Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Cushing’s Syndrome (CS) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Cushing’s Syndrome (CS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight’s “Cushing’s Syndrome – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cushing’s Syndrome, historical and forecasted epidemiology as well as the Cushing’s Syndrome market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542948","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542948"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542948\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}